Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China

Song, Qingbin; Wang, Deguang; Lou, Yu; Li, Changsi; Fang, Changqing; Xu, He; Li, Jianhua

doi:10.1186/1746-1596-6-126

Cited by 47 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In their study of 153 thyroid carcinoma cases, strong, diffuse staining of CK19 was observed in more than 80% of PTC cases, while focal staining was seen in more than 60% of follicular thyroid carcinomas. In agreement with the previous reports [38,39], we observed positive CK19 expression in almost all (95.3%) patients with CSTPTC. In 47 (31.5%), the staining was weak; in 41 (27.5%) medium; and in 54 (36.3%) strong.…”

Section: Discussionsupporting

confidence: 82%

“…They concluded that positive CK19 expression was a predictor of early postoperative recurrence, due to increased invasiveness. Song et al [38] clearly established that the immunohistochemical expression of CK19 in PTC allowed nonmalignant thyroid lesions to be distinguished from PTC, which demonstrated diffuse and strong cytoplasmic CK19 staining; however, they did not describe any correlation between CK19 cytoplasmic staining and postoperative course. Very similar results were obtained by Lam et al [39].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Kaliszewski

Diakowska

Strutyńska−Karpińska

et al. 2017

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Introduction. Cytokeratin-19 (CK19) is recognized as a reliable tumor marker of papillary thyroid carcinoma (PTC). The general prognosis in the classical subtype of PTC (CSTPTC) remains favorable, but some cases can be very aggressive. The aim of this study was to evaluate the localization and intensity of immunohistochemical CK19 expression in CSTPTC and its associations with the clinical and pathological characteristics of patients with CSTPTC in the Silesian region. Material and methods. All the available clinical and histopathological data for 149 patients with CSTPTC from the Silesian region were retrospectively analyzed. The group consisted of 135 (90.6%) women and 14 (9.4%) men (mean age and SD: 52.3 ± 15.0). All these patients with CSTPTC underwent surgery at the same center between 2008 and 2013; the follow-up period was 24 to 90 months (mean and SD: 47 ± 20). Results. In 142 (95.3%) of the patients with CSTPTC, positive cytoplasmic staining of CK19 was found. A higher expression of CK19 was observed in the group of patients without the recurrence of the disease (p = 0.015). CK19 expression was not associated with age, gender, tumor focality, disease stage, tumor size (pT), lymph node involvement (pN), or distant metastases (pM). Conclusions. Decreased CK19 expression in CSTPTC cases with relapse suggests that it plays a role in the carcinoma progression of CSTPTC. The association between lower CK19 expression and patients' unfavorable postoperative course could suggest its possible role as a marker of CSTPTC poor prognosis.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Kaliszewski

Diakowska

Strutyńska−Karpińska

et al. 2017

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…CK19 were found to have high sensitivity (0.75) and specificity (0.95) for PTC. The studies by Song Q [16] show that the expression of CK19 in PTC was much higher than that in the nonmalignant or benign disease cases group (p<0.05), which was 96.37% (425/441) in PTC and in the benign thyroid lesions group was 25.83% (39/151), also show that the diagnostic efficiency of CK19 for PTC was 96.37% (537/592). Bose D's [23] studies give that, all 22 (100%) papillary carcinomas showed diffuse and strong (3+and 4+) CK19 expression, as well as 75% follicular adenomas and 50% multinodular goiters, were positive for CK19; however, it was of weaker intensity (1+and 2+) and focal in distribution.…”

Section: Ck19mentioning

confidence: 98%

“…Clinical research shows that Ki67 could react the proliferate activity of thyroid tumor. Previously studies suggest that the proliferation index of Ki67 in PTC was higher than follicular adenoma, nodular goiter, and normal thyroid tissue; nevertheless, Song Q [16] has found that the positive expression rate of Ki67 in PTC was 40.59% (179/441) through immunehistochemical, and there are no significant difference between PTC and benign thyroid lesions.…”

Section: Ki67mentioning

confidence: 99%

Advances in Tumor Markers for the Early Diagnosis of Papillary Thyroid Carcinoma

Huang

Liu

Cao

et al. 2016

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Papillary Thyroid Carcinoma (PTC) is a common endocrine malignancy and mostly is found in women. Different pathological types of PTC have different biological behaviors. The hidden onset results in difficulties to diagnose the early PTC. With the development of the molecular biology, increasing the number of researchers is a focus on tumor markers. The sensitivity and specificity of these tumor markers are helpful for early diagnosis and therapy of PTC. This review is oriented towards the finding of the potent thyroid cancer markers have enhanced sensitivity and specificity, with diagnostic, prognostic and therapeutic efficiency.

show abstract

“…Cytokeratin 19, RET, galectin-3 and HBME-1 expression in PTC were higher than in benign thyroid diseases, but they are not specific markers for PTC [28,29]. The diagnostic efficiency of CK19 for PTC was slightly better than galectin-3 [30]. Earlier studies have proven that thyroglobulin is a suitable marker for real-time PCR in the evaluation of lymph node metastases in thyroid cancer [26,31].…”

Section: Introductionmentioning

confidence: 99%

Lymph node metastases in papillary thyroid cancer detected by quantitative real-time polymerase chain reaction for thyroglobulin and cytokeratine-19

Kaczka¹,

Fendler²,

Borowiec³

et al. 2013

pjp

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) metastases in the lymph nodes (LNs) were detected by real-time polymerase chain reaction (PCR) for TG and cytokeratin 19 (CK19), and the obtained results were compared with histopathology. 107 LNs from 34 PTC patients were divided into four blocks by a special cutting device -2 for histopathology, while the other 2 were tested by quantitative real-time PCR. Metastases were detected in 20 nodes from 10 (29.4%) patients. TG and CK19 expression levels differed vastly between nodes with and without metastatic cells. ddCt of TG in the genetic material extracted from N0 nodes was 9.97 ±4.20, while in nodes with metastases ddCt was 0.91±4.20 (p < 0.0001). Cytokeratin 19 showed similar results with expression level (ddCt) in N0 nodes of 10.96 ±2.58 vs. 7.73 ±3.63 in nodes with metastases (p < 0.0001). Evaluation of the utility of both parameters showed efficient differentiation of node involvement in the case of TG, with area under the ROC curve (AUC) equal to 0.91 (95% CI: 0.85-0.96). Cytokeratin 19 also allowed for a degree of differentiation but its diagnostic efficacy was lower (AUC 0.76, 95% CI: 0.64-0.88). The combined TG and CK19 quantitative real-time PCR could be used to select a previously missed group of patients with nodal involvement undetectable by standard histopathology.

show abstract

Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China

Cited by 47 publications

References 30 publications

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Advances in Tumor Markers for the Early Diagnosis of Papillary Thyroid Carcinoma

Lymph node metastases in papillary thyroid cancer detected by quantitative real-time polymerase chain reaction for thyroglobulin and cytokeratine-19

Contact Info

Product

Resources

About